John Davison Simon Doe
10.1016/j.rmcr.2021.101557
Respir Med Case Rep
2021 Nov 17;34:101557.
acq, asthma control questionnaire bid, twice daily benralizumab biologics eosinophilia fev1, forced expiratory volume in 1 second fvc, forced vital capacity feno, fractional exhaled nitric oxide ics, inhaled corticosteroid(s) il, interleukin im, intramuscular ig, immunoglobulin laba, long-acting β2-agonist ocs, oral corticosteroid(s) q4w, every 4 weeks q8w, every 8 weeks qd, once daily quality of life sac, severe asthma center sc, subcutaneously severe eosinophilic asthma
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/34877251/
Case Reports
PMC8633044
34877251
A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
2021